Trade Group Urges FDA To Look Beyond Scale In Regulating Nanotechnology
This article was originally published in The Rose Sheet
Executive Summary
FDA should not use size alone to regulate nanotechnology, the Consumer Healthcare Products Association says.
You may also be interested in...
FDA Nanotech Guidance Draws Industry Comment On Particle Size Criteria
FDA's draft guidance to industry suggesting that ingredients up to 1 micrometer in size still qualify as nanomaterials if they exhibit “altered properties” should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
FDA Nanotech Guidance Draws Industry Comment On Particle Size Criteria
FDA's draft guidance to industry suggesting that ingredients up to 1 micrometer in size still qualify as nanomaterials if they exhibit “altered properties” should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.